Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05377905 · ClinicalTrials.gov registry record · Phase 1
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
A Phase 1 study of Cutaneous Squamous Cell Carcinoma and Skin Cancers - Squamous Cell Carcinoma, sponsored by Falo, Louis, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05377905: Recruiting Phase 1 study of Cutaneous Squamous Cell Carcinoma and Skin Cancers - Squamous Cell Carcinoma, sponsored by Falo, Louis, MD.
NCT05377905 is a Phase 1 study of Cutaneous Squamous Cell Carcinoma and Skin Cancers - Squamous Cell Carcinoma that is actively recruiting participants, run by Falo, Louis, MD. The registered enrollment target is 48 participants, below the 90-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05377905, a Phase 1 study of Cutaneous Squamous Cell Carcinoma and Skin Cancers - Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Falo, Louis, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of doxorubicin, a chemotherapy agent. The overall goal of this study is to test the safety and effectiveness of these patches. The investigators have established the highest tolerated dose at 50 micrograms in a previous study for a different type of cancer that affects the skin. The investigators will thoroughly evaluate the skin where the patches are applied.
Primary Outcome
Evaluated by assessing adverse events grade 2 or higher related to the MNA-D intervention
Conditions Studied
Interventions
- DRUG Microneedle Array Doxorubicin (MNA-D)
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05377905 shows while recruiting
NCT05377905 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 90-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with Cutaneous Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Microneedle Array Doxorubicin (MNA-D) is the first listed.
NCT05377905 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05377905 about?
NCT05377905 is a clinical study titled "Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)". The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of doxorubicin, a chemoth...
What is the current status of trial NCT05377905?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-09-13. Estimated completion is 2026-12-31.
What conditions does trial NCT05377905 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05377905?
The interventions under investigation include: Microneedle Array Doxorubicin (MNA-D) (DRUG).
Who is sponsoring clinical trial NCT05377905?
This trial is sponsored by Falo, Louis, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05377905 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05377905's enrollment target sits among peer trials
48 10th of 18 higher than 9 of 18 other Cutaneous Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI